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Abstract: The management of chronic lymphocytic leukemia (CLL) has evolved dramatically in the last decade. For the first time, 
clinical intervention has been shown to alter the natural history of the disease. Considerable efforts are focussing on better patient 
selection and response prediction, and it is expected that the publication of the first 200 CLL genomes will spark new insights into risk 
stratification of CLL patients. Besides, many new agents are being evaluated on their own and in combination therapy in early and late 
Phase clinical studies. Here, we provide a general clinical introduction into CLL including diagnosis and prognostic markers followed 
by a summary of the current state-of-the-art treatment. We point to areas of continued clinical research in particular for patients with 
co-morbidities and highlight the challenges in managing refractory disease.
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Background
Chronic  lymphocytic  leukemia  (CLL)  is  the  most 
common  adult  leukemia.1  At  diagnosis,  85%  of 
patients are older than 65 years of age. Therefore, this 
leukemia represents a significant challenge for health-
care systems of aging populations. Treatment of CLL 
has evolved significantly in recent years. In younger 
patients without co-morbidities, treatment goals have 
shifted from symptom control to achieving long last-
ing  remissions  or  even  cure. The  advent  of  many 
new agents, in particular anti-CD20 antibodies, has 
increased patients’ choice of treatment and improved 
clinical outcomes. In particular, the addition of ritux-
imab  to  the  chemotherapy  backbone  has  changed 
the  natural  history  of  CLL  by  improving  overall 
  survival. However, many issues remain unresolved: 
the increasing use of more toxic and expensive thera-
peutic regimens demands better risk stratification and 
response prediction. The question of early treatment 
versus active surveillance has re-emerged as an area 
of research interest. Whether achieving eradication 
of minimal residual disease (MRD) should become a 
treatment goal in younger patients and what the role of 
maintenance treatment should be remains unknown. 
The treatment of patients with high-risk and purine-
analogue refractory CLL remains challenging in clin-
ical practice and optimal strategies for older patients 
aimed at quality of life rather than overall survival, 
need to be developed.
This  review  attempts  to  address  some  of  these 
issues by providing a general introduction into CLL 
followed by a detailed description of the current man-
agement of both fit and frail patients with CLL. To 
this, we have focused in particular on the International 
Workshop for CLL (iwCLL) and UK British Society 
of Haematology (BSH) CLL guidelines.2,3 The third 
part of the review deals with some of the novel thera-
pies currently under investigation.
Molecular pathogenesis in cLL
It is generally accepted that CLL derives from   antigen 
experienced  mature  B  cells  homing  to    secondary 
lymphoid organs. Defects in the cell death   machinery 
combined  with  the  contribution  from  the  stromal 
microenvironment  and  accessory  cells  lead  to 
  expansion of an abnormal lymphoid cell population. 
Antigenic input and B cell receptor (BCR) signaling 
play an important role in this process.
The BCR is the key survival molecule for normal 
and malignant B cells.4 Following antigen engagement 
of  BCR,  activation  of  intracellular  protein  kinases 
occurs which allows secondary downstream signal-
ling involving pathways such as PI3-K/AKT/mTOR, 
ultimately  mediating  changes  in  cell  proliferation 
and  cell  survival.  Inhibition  of  BCR  signalling  is 
therefore an important mechanism of controlling the 
proliferation and survival of CLL cells. 
Prolonged survival of malignant B cells is a feature 
of CLL thought to result from an imbalance between 
pro- and anti-  apoptotic members of the Bcl-2 family. 
As Bcl-2 is overexpressed in CLL cells this is another 
area of active drug development.5 Finally it is thought 
that soluble factors such as cytokines, stromal cells, 
T cells and nurse like cells are involved in maintain-
ing the CLL cell’s viability within the bone marrow 
or lymph node and allowing development of drug 
resistance.6 Disruption of this microenvironment and 
removal of these protective stimuli may lead to CLL 
cell death. We will discuss treatments targeting these 
pathobiological processes in more detail below.
Diagnosis and staging
CLL is a heterogenous disease with a wide variabil-
ity in disease presentation and course. While some 
patients  with  CLL  will  never  require  therapeutic 
intervention, many others require multiple lines of 
chemotherapy and often die from the disease. Current 
guidelines outline diagnosis and staging of CLL based 
on the characteristic immunophenotype of CD19 and 
CD5  positivity  present  on  .5  ×  109/L  peripheral 
blood B lymphocytes.2 The iwCLL guidelines recom-
mend disease assessment using Rai or Binet Staging 
systems to guide treatment initiation as these provide 
a reliable prediction of a patient’s prognosis based 
solely on physical examination and blood counts.7,8
prognosis
A variety of prognostic biomarkers have been stud-
ied in CLL.9 Analysis of somatic mutations of the 
immunoglobulin  heavy  chain  variable  (IGHV) 
region is used to stratify CLL patients into two dis-
tinct biological and prognostic groups on the basis of 
whether the IGHV genes are hypermutated (,98% 
homology  with  germline)  or  unmutated  (./=98%   
homology).10,11 As this is a difficult and expensive test 
to perform routinely in clinical laboratories, surrogate State-of-the-art in CLL
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markers such as zeta associated protein 70 (ZAP70) 
and CD38 expression have been evaluated.12–15 The 
use of a combination of both CD38 expression and 
ZAP70 can classify CLL patients in to 2 risk groups 
with a double negative result equating to an excellent 
prognosis and double positive a poor prognosis.16
Cytogenetic abnormalities are detected in approxi-
mately 80% of CLL patients using interphase fluo-
rescence in situ hybridisation (FISH).17 Dohner et al 
investigated  325  mainly  untreated  CLL  patients 
and identified five prognostic categories. Of these, 
patients with 17p deletions and 11q deletions had the 
worst outcome. The median treatment-free interval 
for these groups was 9 and 13 months, respectively. 
More recently, it has been shown that the addition of 
rituximab to standard chemotherapy may overcome 
the adverse prognostic significance of 11q deletions 
but not of del17p.18,19
Mono-  or  bi-allelic  mutations  of  TP53  without 
del17p also confer a poor prognosis and chemother-
apy refractoriness. Del17p/TP53 abnormalities occur 
in about 8% of patients at diagnosis and 25% of flu-
darabine refractory cases.20,21 It is therefore recom-
mended to test for deletions and/or mutations of TP53 
before each course of treatment.
Response prediction Using Whole 
Genome Approaches
As outlined in more detail below, treatment of patients 
with  CLL  has  evolved  in  recent  years  and  many 
patients are exposed to potentially more toxic agents 
like  purine  analogues  or  alemtuzumab.  Besides, 
modern chemo-immunotherapy is significantly more 
expensive than single agent chlorambucil. There is 
therefore an urgent need to identify responders and 
non-responders early in order to avoid inappropriate 
drug  use  leading  to  unnecessary  side-effects  and 
expense.  Advances  in  whole  genome  array  and 
sequencing technology will likely transform response 
prediction over the next decade by allowing us to iden-
tify genetic markers which can direct treatment choice.
Copy  number  alterations  (CNAs),  which  are 
deletions  or  amplifications  of  chromosomal  mate-
rial, or uniparental disomy, can be revealed by high-
  resolution genome-wide arrays. Genomic complexity 
is defined by the presence of more than 3 CNAs or 
a total length of CNAs of .5 megabases and has 
been  shown  to  correlate  with  disease  progression, 
clonal evolution and refractory disease in CLL.22,23 
Our own data on paired pre-treatment and relapse 
samples  extends  these  analyses  by  showing  that 
the c  omplexity of CNAs increases over time in the 
same patient and pinpoints to candidate drivers of dis-
ease progression.24 Whole genome sequencing (WGS) 
and whole exome sequencing (WES) of 200 patients 
and their germline controls, has revealed a complex 
mutation  spectrum  in  CLL,  mirroring  its  clinical 
and biological heterogeneity.25–27 Recurrent gain-of-
  function   mutations in Notch1 were found in 12% of 
CLL patients, with a higher proportion found in che-
motherapy-refractory CLL and during progression to 
Richter’s transformation. These findings are supported 
by two further studies associating Notch1 mutations 
with  clinically  aggressive  CLL.28,29  Importantly, 
although Notch1 mutated patients lacked TP53 dis-
ruption in .90% of cases, the overall survival (OS) 
predicted by Notch1 mutations was similar to that of 
TP53 mutated/deleted CLL. Mutations in the splicing 
factor SF3B1 are present in ∼10% of CLL patients 
and also predict poor prognosis.26,30 However, most 
mutations identified by genome-wide sequencing are 
non-recurrent or recurrent at low frequency. While the 
results of these novel technologies are unravelling the 
pathobiological processes in CLL, prospective vali-
dation of their clinical significance is required prior 
to implementation in clinical practice.
Treatment
General principles
When to treat?
The treatment of CLL poses many challenges, not least 
to convey to patients that no treatment is indicated for 
their newly diagnosed leukaemia. that no treatment is 
indicated. Although  treatment  indications  have  been 
clearly defined,2 the exact time when treatment should be 
initiated can be subjective and dependent more on sever-
ity of symptoms then objective criteria. In discussions 
with  patients  and  relatives,  the  patient’s  preference 
should be taken into consideration whenever possible, 
as CLL is a chronic cancerous condition that patients live 
with for years. A meta-analysis of initial studies using 
chlorambucil with or without prednisolone, did not show 
any benefit for early treatment versus watch and wait.31 
This question is currently being revisited by the German 
CLL Study Group using modern chemoimmunotherapy   
versus watch and wait in high-risk disease.Clifford and Schuh
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Aims of treatment
Only 15% of patients diagnosed with CLL are under 
the age of 65. On the other hand, 66% of patients 
recruited into the German CLL trials were younger 
than  64  (Goede,  IX  AROSA  Workshop  2004). 
  Similar  recruitment  figures  are  found  around  the 
world.   Western societies are confronted with a rise 
in  the  elderly  population  and  an  improvement  in 
life    expectancy.  There  is  therefore  a  clinical  need 
to design specific treatments for older patients who 
often have multiple co-morbidities.32,33 It is critical to 
define the goals of therapeutic intervention from the 
outset together with patients and their families.
Apart from prolonging life to the predicted life 
expectancy  of  an  individual,  treatment  of  elderly 
patients with cancer should aim to improve or maintain 
quality of life. Although age is a helpful indicator of 
what the treatment goal should be, there is a consider-
able grey area in patients between 55 and 70 years of 
age. A patient’s performance status rather than their 
chronological age can be more informative. Scoring 
systems such as the Cumulative Illness Rating Scale 
(CIRS) to establish and quantify co-morbidities have 
been validated in the elderly and are being used as part 
of clinical trials.34 Their value in day-to-day clinical 
practice is less clear. The GCLLSG utilises this scor-
ing system to stratify patients based on CIRS score; 
‘Go-Go’ patients have a low co-morbidity score and 
a normal creatinine clearance, and ‘Slow-Go’ patients 
have relevant comorbidities.
On the other hand, in young patients without co-
morbidities (Go-Go), curative options should at least 
be considered.
Intimately  linked  to  these  considerations  is  the 
desired depth of response. There is clear evidence 
that minimal residual disease (MRD) eradication is 
associated with a better overall survival as well as 
progression  free  survival  (PFS)  providing  a  clear 
rationale  for  using  the  most  effective  treatment 
available up-front.18,35 This is also corroborated by 
emerging long term follow up data suggesting that 
sequential treatment with chlorambucil followed by 
fludarabine  shortens  OS  compared  to  fludarabine 
treatment up-front,36 and therefore   implying that the 
CLL diagnosis
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Figure 1. Flow diagram of proposed treatment algorithm for CLL.
Abbreviations: W and W, watch and wait; FCR, fludarabine cyclophosphamide rituximab; Clb, chlorambucil; PFS, progression free survival; BMT, bone 
  marrow transplantation.State-of-the-art in CLL
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most effective treatment should be given preference. 
However, whether eradication of MRD should become 
a  treatment  goal  and  obtained  with  maintenance 
treatment remains an area of active research.37
The treatment algorithm proposed in this review 
is  summarized  in  Figure  1. A  summary  of  pivotal 
clinical  trials  defining  treatment  for  patients  with 
CLL is given in Table 1.
Table 1. Summary of pivotal phase II/ phase III trial in CLL.
1st line treatment Reference Median age patient numbers Results
GO-GO patients
FC v F v Clb Catovsky LrF 
CLL438
65 777 Cr: 35% v 7% (P , 0.001) 
Orr: 94% v 80% (P , 0.001) v 72% 
pFS at 5 years: 36% v 10% v 10% 
(P , 0.001)
F v Clb rai39 64 350 Cr: 20% v 4% (P , 0.001) 
Orr: 63% v 37% (P , 0.001) 
pFS median: 20 v 14 months (P , 0.001)
FCr v FC Hallek40 61 817 Cr: 44% v 22% (P , 0.0001) 
Orr: 90 v 80% (P , 0.0001) 
3 yr pFS: 65% v 45% (P , 0.001) 
OS: 87% v 83% (P = 0.01)
sLOW-GO patients
Bendamustine vs Clb Knauf65 63 319 Cr: 31% v 2% 
Orr: 68% v 31% (P , 0.0001) 
pFS median: 21.6 v 8.3 months 
(P , 0.0001)
F v Clb eichhorst63 70 Orr: 72% v 51% (P = 0.003) 
Cr: 7% v 0% (P = 0.011) 
pFS: 19 v 18 months (P = 0.7)
Relapse treatment
GO-GO patients
  FCr v FC robak41 63 552 Cr: 24.3% v 13% (P , 0.001) 
Orr: 69.6% v 58% (P = 0.0034) 
pFS median: 30.6 v 20.6 months 
(P , 0.001) 
OS median: 46 v 64 months (P = 0.15)
SLOW-GO patients
  No randomized trials
High risk patients
GO-GO patients
  Alemtuzumab S/C Stilgenbauer 
CLL2H study20
63 103 Cr 4% 
Orr 34% 
pFS median: 7.7 months 
OS median: 19.1 months
    Alemtuzumab 
prednisolone
pettitt45 56 52 Cr: 36% 
Orr: 85% 
pFS: 11.8 months 
OS: 23.5 months
  CFAr parikh46 59 60 Cr: 70% (14 patients w p53  
del – Cr 57%) 
Orr: 92% 
pFS median: 33 months
SLOW-GO patients 
  Ofatumumab
 
Wierda68
 
63
 
138
 
Cr: 0% 
Orr: 53% 
pFS median: 5.8 months 
OS median: 14.5 monthsClifford and Schuh
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Go-Go
1st line treatment
Over the last decade, considerable progress has been 
made in the treatment of physically fit patients with 
CLL. Purine-analogue combinations have impro  ved 
treatment  outcomes.38,39  Importantly,  we  have   
  witnessed a paradigm shift in the management of 
CLL changing for the first time the natural history of 
the disease. The German CLL8 study compared FC 
versus FCR and demonstrated that therapeutic inter-
vention in CLL led to an improved overall survival 
in patients with CIRS scores of ,6.40 There was no 
upper age limit for this study, but the median age was 
61 years. Only 10% of patients were >/=70 years old.   
Overall response rates (ORR) were 80% vs 90% 
for FC and FCR, respectively. At 3 years after ran-
domisation, 65% of patients in the chemoimmuno-
therapy group were free of progression compared 
with 45% in the chemotherapy group (hazard ratio 
0.56 [95% CI 0.46–0.69], P , 0.0001); 87% were 
alive versus 83%, respectively (0.67 [0.48–0.92]; 
P  = 0.01).40 Patients with del11q benefitted par-
ticularly  from  the  addition  of  rituximab.  On  the 
other hand, neither FC nor FCR were effective at 
treating patients with del17p. Following the pub-
lication of this study, FCR is considered the new 
standard of care for fit patients with CLL in first 
line treatment.
relapse treatment
FCR combination treatment is also effective in the 
relapse setting. The REACH study included patients 
at first relapse.41 However, the majority of patients 
in the study had previously received chlorambucil 
and were rituximab naïve. After a median   follow-up 
time of 25 months, rituximab significantly improved 
  progression-free  survival  (PFS)  in  patients  with 
previously  treated  CLL    (hazard  ratio:  0.65;   
P value < 0.001; median PFS: 30.6 months for R-FC 
v 20.6 months for FC). Relapse data on patients 
previously  treated  with  FCR  is  emerging.  In  a 
single centre study, 33 of 112 patients who relapsed 
after initial treatment with FCR were retreated with 
FCR. Patients who relapsed after 3 years had an 
ORR and CR of 86% and 23% compared to 54% 
and 0% for those relapsing within 3 years.42 On the 
basis of these data, FCR has therefore become the 
standard  relapse  treatment  for  GO-GO  patients. 
However,  there  is  still  some  debate  around  the 
definition of FCR refractoriness. Bearing in mind 
side-effects from FCR and it’s cost, it is reasonable 
to assume that re-treatment with FCR should only 
be attempted if the PFS after first line FCR is more 
than 2 years.
patients with del17p/Tp53 mutation and 
purine analogue refractory patients
Patients  with  deletions  of  chromosome  17p  or 
TP53 mutation or purine analogue refractory disease 
have a poor prognosis and usually show only limited 
response to salvage chemotherapy. Alternative treat-
ments are therefore urgently required. Subcutaneous 
administration of alemtuzumab20,43,44 is as effective 
and safe as intravenous administration with response 
rates  ranging  between  22%  and  34%  and  median 
overall survival times between 10 and 19 months.
Despite the absence of randomised studies, it has 
become the “standard of care” for patients with TP53 
deleted/mutated  or  purine  analogue  refractory  dis-
ease. Alemtuzumab  is  not  effective  in  patients  with 
bulky lymphadenopathy. Combination treatment with 
high dose steroids, in particular high dose methylpred-
nisolone  (1  g/m2/d  ×  5  days)  or  pulsed  dexametha-
sone (40 mg/d × 4 days every 14 days), is therefore 
being  evaluated.  An  initial  Phase  2  study  showed 
improved ORR and CR rates of 85% and 36%, respec-
tively, and a median PFS and OS of 11.8 months and 
23.5 months.45
Further  intensification  has  been  achieved  by 
combining  alemtuzumab  to  FCR  treatment  (CFAR 
  regimen). Using CFAR, patients with high-risk CLL 
achieved ORR of 92% and CR rates of 70% in first 
line.46   However, combinations of alemtuzumab with 
fludarabine  are  not  recommended  outside  clini-
cal trials due to the increased rate of fatal infectious 
episodes.47
Allogeneic transplantation
For younger patients without co-morbidities and high-
risk CLL, bone marrow transplantation to consolidate 
remission should be considered.48
High risk CLL was defined by the EBMT CLL 
transplant consensus49 as:
•	 Non-response or early relapse (within 12 months) 
after purine analogue-containing therapyState-of-the-art in CLL
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•	 Relapse (within 24 months) after purine analogue 
combination therapy or treatment of similar effi-
cacy (ie, autologous stem cell transplantation)
•	 del17p/TP53 deletion/mutation requiring treatment
An EBMT retrospective study of 44 transplants 
performed between 1995 and 2006 for del17p CLL 
showed that about one third of patients achieved long-
term remission.50 A retrospective case control study 
suggested a survival advantage for patients with high 
risk CLL treated with reduced intensity conditioning 
(RIC) BMT.51 Data from Seattle on 82 patients under-
going RIC-allografting quotes 5-year incidences of 
non-relapse  mortality  (NRM),  progression/relapse, 
overall  survival,  and  progression-free  survival  of 
23%, 38%, 50%, and 39%, respectively.52 In this study, 
a lymph node size of >/= 5cm, but not cytogenetic 
abnormalities, was associated with outcome. In the 
GCLLSG CLL3X trial, the 4-year EFS after RIC-allo 
BMT was 42% and similar for all genetic subtypes, 
indicating  that  del17p  loses  its  adverse  prognostic 
significance in this therapeutic context.48
Overall, outcome data from conventional BMT 
and RIC allo-BMT demonstrate a higher TRM in 
CLL compared to other diseases. The reasons for 
this are poorly understood, but might be related to 
the  increased  age,  secondary  immunodeficiency 
and possibly to the T-cell depleting induction treat-
ment.  Autologous  PBSCT  are  not  performed  in 
CLL due to the high risk of MDS/AML and the 
lack of overall survival benefit despite improved 
PFS and EFS.53,54
Maintenance
The observation that MRD negative remissions are 
associated  with  prolonged  PFS  both  in  previously 
untreated55 and relapsed cases56 has led to studies of 
additional treatment in patients with residual disease 
after induction therapy.
The use of alemtuzumab following initial therapy 
with fludarabine-based regimens has improved CR 
rates, led to MRD eradication and prolonged PFS. An 
initial Phase 3 trial revealed ORR of 46% with clear-
ance of MRD in 11 of 29 patients.57 The GCLLSG 
randomised  patients  to  receive  alemtuzumab  con-
solidation  or  no  treatment  after  first-line  fludara-
bine +/− cyclophosphamide treatment.58 Out of 22 
evaluable patients, 11 of whom had alemtuzumab, 
the  median  PFS  at  48  months  was  significantly 
improved in the treatment arm (not reached versus 
20.6 months, P = 0.004). However infectious com-
plication rates necessitated early closure of this trial. 
A further Phase 2 trial evaluated subcutaneous alem-
tuzumab  in  the  consolidation  setting.59  Of  the  29 
evaluable patients, 23 had a response. The majority 
of treatment related adverse events were grade 1/2 
and  four  patients  experienced  serious  infections. 
Careful attention to the timing of consolidation ther-
apy and to antimicrobial prophylaxis and treatment 
is warranted.
Preliminary data suggest that consolidation ther-
apy with rituximab may also prolong PFS. Foon et al 
combined a lower dose of fludarabine and cyclophos-
phamide  (20  mg/m2  and  150  mg/m2,  respectively, 
× 3 days every 4 weeks) with standard dose rituximab 
(500 mg/m2 every 14 days) including rituximab main-
tenance  every  3  months  until  relapse  (FCR-Lite).60 
Complete responses were seen in 77% of patients, 
none of whom had relapsed at a median follow up 
time of 22.3 months. Among the 11 PRs, nine patients 
progressed and 5 died from CLL-related complication. 
The impact of maintenance therapy in this trial is yet 
to be realised. The Spanish CLL Study Group recently 
presented the final results of a Phase 2 clinical trial 
evaluating rituximab, fludarabine, cyclophosphamide, 
and  mitoxantrone  (R-FCM)  followed  by  rituximab 
maintenance for front-line treatment of CLL.61 Patients 
achieving a CR or PR after 6 cycles of R-FCM received 
rituximab  maintenance  every  3  months  (375  mg/
m2)  for  2  years.  64  patients  completed  .4  cycles 
of maintenance and were evaluable for a response. 
  Neutropenia  was  observed  in  31%  of  patients  and 
16  patients  experienced  grade  3/4  infectious  com-
plications. There were 2 deaths, one from multifocal 
leukoencephalopaty  and  one  from  hemophagocytic 
syndrome. Among 35 patients in MRD-negative CR 
after R-FCM induc  tion, 22 maintained the MRD-neg-
ative status, 9 (25.7%) switched from MRD-negative 
to MRD-positive, and 4 failed treatment. Median time 
to  conversion  from  negative  to  positive  MRD  was 
45.4 months, which is significantly longer compared 
to FCM only treated patients (45.4 vs. 16.4 months; 
P = 0.011).35 This maintenance regime shows activ-
ity in CLL and may improve outcomes by impacting 
on MRD negativity, however this benefit needs to be 
tempered by the toxicity profile.Clifford and Schuh
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slow-Go
There is currently no standard of care for patients 
with CLL older than 70 years of age or patients with 
co-morbidities.
1st line treatment
Chlorambucil has been in use for the past 40 years.31 
Approximately 70% of 1st line patients are expected 
to  obtain  a  response  to  chlorambucil.  However, 
complete remissions are rare and the mean PFS is 
18 months.38 More recently, chlorambucil was com-
bined with rituximab in an open label Phase II study.62 
Across trial comparison of response rates would sug-
gest that this regimen might induce more responses 
(ORR: 84%) and a longer PFS.
The use of purine analogues in the elderly remains 
an area of active research. Only 10% of patients in 
the German CLL8 study were over the age of 70 and 
none had CIRS scores of .6. Besides, there is no 
overall  survival  benefit  for  elderly  patients  treated 
with fludarabine versus chlorambucil.63 Bendamus-
tine,64  a  purine  analogue-alkylator  hybrid  used  in 
Eastern  Germany  for  the  past  40  years,  compared 
favourably to chlorambucil in a frontline study for 
elderly patients.65 However, for reasons not entirely 
understood, results in the chlorambucil control arm 
were significantly worse in this study compared to 
the UK CLL4 trial. Bendamustine was well tolerated 
with little myelotoxicity. As it is metabolised by the 
liver, it is of particular benefit in patients with renal 
impairment.
relapse treatment
Patients with PFS of over one year can be re-treated 
with 1st line single agent chemotherapy. Bendamus-
tine,  in  combination  with  rituximab,  also  showed 
significant  activity  in  relapsed/refractory  patients.66   
In this study, 37% of patients were over the age of 70 
and 42% had a creatinine clearance of ,70 ml/min. 
60% of patients experienced at least one Grade 3–4 
adverse events during the course of treatment. The 
ORR was 59% and the median PFS was 15 months. 
Patients with del17p and fludarabine refractory patients 
benefitted least from BR treatment. The bendamustine 
and rituximab combination is being taken forward by 
the German CLL study group in a direct head to head 
comparison with FCR in GO-GO patients.
refractory elderly patients
Refractory disease in older patients and patients with 
co-morbidities, who are not eligible for BMT, represents 
one of the major challenges ahead. Refractory treatments 
such as alemtuzumab and high dose methylprednisolone 
are used, but often with considerable side-effects.
Second generation monoclonal anti-CD20 anti-
bodies  represent  an  attractive  alternative  for  this 
group of patients. Ofatumumab, a fully humanised 
second-generation anti-CD20 antibody has proven 
efficacy in relapsed CLL. In an initial Phase 1/2 study 
Coiffier et al enrolled 33 relapsed CLL patients and 
achieved a 50% ORR.67 The drug obtained acceler-
ated FDA approval for treatment of fludarabine and 
alemtuzumab refractory (FA-ref) disease subsequent 
to the pivotal phase II study on 138 patients with 
either FA-ref or bulky fludarabine refractory (BF-ref) 
disease. This study showed a 55% overall response 
rate  which  compared  favourably  to  the  expected 
15%.68 Median progression-free survival and overall 
survival times were 5.7 and 13.7 months in the FA-
ref group, respectively, and 5.9 and 15.4 months in 
the BF-ref group, respectively. Interestingly, a sub-
sequent subgroup analysis showed that response to 
ofatumumab was independent from previous ritux-
imab treatment and rituximab refractoriness.69,70
novel Therapies, Therapies Under 
Development
As conventional chemotherapy regimes are toxic thus 
limiting their application in many elderly CLL patients, 
and high risk CLL patients have limited responses to 
current treatment options, novel t  reatment strategies 
are required. Molecular targeted treatments that by 
pass resistance mechanisms to cytotoxic drugs are 
particularly desirable. 
More recently, a number of relevant signals down-
stream of the BCR or BCR co-stimulatory molecules, 
have been implicated in CLL. Inhibitors to the BCR 
  signaling pathway, agents directed at re-activating 
the death pathways and immunomodulatory agents 
have  all  shown  promising  activity  in  early  phase 
studies.
Novel anti-cd20 antibodies
A  plethora  of  therapeutic  monoclonal  antibodies 
are  currently  undergoing  pre-clinical  and  clinical State-of-the-art in CLL
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evaluation.71  GA101  is  well  tolerated  and,  like 
ofatumumab, is significantly more potent and effec-
tive in depleting B cells than rituximab in preclinical 
models.72–74 In a Phase I study of 13 heavily pretreated 
CLL  patients,  GA101  had  a  similar  safety  pro-
file to that observed in Non-Hodgkins Lymphoma 
patients and had an ORR of 62%.75 Phase II trials are 
currently ongoing.
Lenalidomide
Lenalidomide,  an  immunomodulatory  drug  with 
more  potent  activity  than  thalidomide,  has  shown 
tolerability and efficacy in relapsed refractory CLL 
patients.76,77 Ferrajolis et al studied 44 patients who 
had  received  an  average  of  5  previous  treatments. 
Following lenalidomide, the ORR was 32% with CR 
rates of 3%, however 6 to 9 months were needed to 
achieve optimal response. Based on these promising 
results  in  a  heavily  pretreated  population,  upfront 
treatment with lenalidomide was evaluated in 2 fur-
ther studies.78,79 Following initial toxic events of sep-
sis and tumour lysis in the first 2 patients enrolled, 
the protocol was changed to a more conservative dos-
ing schedule (median dose of 10 mg od) including 
dose escalation. Badoux et al recently published their 
results on 60 previously untreated CLL patients aged 
65 or over. After a median follow up of 29 months, 
88%  patients  are  alive  and  53%  remain  on  treat-
ment  with  an  estimated  2-year  PFS  of  60%  (95% 
CI, 46%–72%). An ORR of 65% with a 10% CR 
rate was achieved. Serious infections or neutropenia 
of >/= Grade 3 were noted in 13% of patients with 
one fatal infection. Patients with 17p deletion iden-
tified by FISH (n = 6) were less likely to achieve a 
response (P = 0.001). Trials combining lenalidomide 
with rituximab or fludarabine and rituximab and the 
evaluation of low-dose lenalidomide in the mainte-
nance setting are still in progress.
Flavopiridol
Flavopiridol, an inhibitor of cyclin-dependent kinases, 
shows activity in CLL patients including high-risk 
groups  with  17p  deletions.80  Lin  et  al  evaluated   
64 patients with a median age of 60 years and a median 
of 4 prior therapies in a Phase II trial of single-agent 
flavopiridol. 34 patients achieved a response (53%) 
including 57% and 50% of patients with del17p or 
del11q,  respectively.  Median  progression  free  sur-
vival  was  10  to  12  months  across  all  cytogenetic 
risk groups. Tumour lysis syndrome was a signifi-
cant dose-limiting toxicity and subsequent trials will 
amend the dosing schedule based on these results.
Inhibitors of B-cell receptor signalling
B cell receptor signaling influences disease progres-
sion in CLL and many small molecule inhibitors tar-
geting various downstream signalling pathways are 
under investigation. Promising clinical responses have 
been observed with fostamatinib disodium (FosD),   
a  SYK  inhibitor;  PCI-32765,  a  Bruton  tyrosine 
kinase inhibitor; and CAL-101, a selective inhibitor 
of PI3K.4,81 These drugs are available in oral prepara-
tions and are given as continuous treatment. Initial 
rapid resolution of lymphadenoapathy is accompa-
nied by a transient rebound lymphocytosis. After a 
number of months of continuous therapy remissions 
can be achieved in a substantial number of patients. 
Further preclinical and clinical series are needed to 
outline toxicities, efficacy and potential drug combi-
nations in CLL patients. BCR inhibitors are currently 
being evaluated in relapsed patients in combination 
with bendamustine and/or rituximab.
Bcl-2 antagonists
Bcl-2 is known to have anti-apoptotic functions and 
is  over-expressed  in  many  lymphoid  malignancies 
including CLL. Oblimersen, a Bcl-2 antisense mol-
ecule has shown activity in relapsed CLL patients.82 
A  phase  III  study  randomised  241  relapsed  CLL 
patients to receive fludarabine and cyclophosphamide, 
with or without oblimersen.83 The rate of CR plus 
nodular PR in the oblimersen group versus FC alone 
was 17% compared with 7%. Obatoclax is a small 
molecule pan-Bcl-2 inhibitor which has shown prom-
ising clinical activity in relapsed CLL.84   Neurological 
toxicity of unclear aetiology was a manageable side 
effect. A phase III study in combination with FCR 
is  planned.  An  orally  bioavailable  BH3  mimetic, 
  Navitoclax, inhibits several of the Bcl-2 family mem-
bers and is active in CLL.85,86 Recently, it has been 
reported that combining this agent with FCR or BR 
in relapsed CLL patients has anti-tumour activity and 
is well tolerated.87 In the BR arm the ORR was 81% 
(13/16) including responses in TP53 deleted patients. Clifford and Schuh
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The  most  common  grade  3/4  adverse  events  were 
thrombocytopaenia and neutropaenia. Further results 
from this trial are awaited.
complications
Infections
Prevention  and  treatment  of  disease  complications 
should be the focus of attention when seeing patients 
in follow-up clinics. Annual influenza vaccination and 
vaccinations against encapsulated bacteria should be 
considered, especially early on in the disease when 
secondary immunodeficiency has not yet developed 
and  patients  are  more  likely  to  mount  immune 
responses.88 Patients with bronchiectasis or chronic 
infections  might  be  considered  for  antibiotic  pro-
phylaxis or intravenous immunoglobulins.89   Atypical 
infections  with  pneumocystis  jirovecii,  listeria, 
mycobacteria,  CMV  re-activation,  Herpes  simplex 
and Herpes zoster should be part of the differential 
diagnosis especially in pre-treated patients.
Autoimmune complications
Patients with CLL present with a range of autoim-
mune  complications,  most  commonly  autoimmune 
haemolytic anaemia and idiopathic thrombocytopae-
nia purpura. These can be controlled with steroids in 
two thirds of patients. Second line therapies include 
rituximab,  splenectomy,  alemtuzumab  or  steroid 
sparing agents such as cyclosporine. Treatment of the 
underlying CLL should be considered if appropriate.90 
Other  immune-complications  have  been  described 
and  patients  with  CLL  can  have  paraproteins  and 
cryoglobulins.
richter’s syndrome
Richter’s Syndrome (RS)91–93 is a rare complication 
of CLL, occurring in about 2.2%–15% of patients 
depending on the series. The underlying pathology 
can be a diffuse large B-cell lymphoma (DLBCL) or 
rarely Hodgkin’s disease.94 Patients with RS typically 
present with a history of CLL, severe B symptoms, 
elevated  lactate  dehydrogenase  levels,  and  rapidly 
enlarging lymph nodes. Diagnosis is confirmed by 
biopsy of an enlarging lymph node or other involved 
site. RS is intrinsically more chemo-resistant than de 
novo DLBCL, and displays high-risk genomic aber-
rations,  such  as  del17p  and  TP53  mutations,  that 
render  these  disorders  refractory  to  conventional 
regimens.29,95  Extensive  disease  involvement,  high 
tumour burden and rapid disease kinetics are com-
mon features of RS affecting up to 50% of cases.   
In addition, tumour burden is an independent predictor 
of poor survival in RS patients. Patient frailty because 
of poor performance status, poor bone marrow func-
tion or immunodeficiency is a common feature in the 
context of RS, and represents an independent predic-
tor of poor survival after transformation.
The  frailty  of  RS  patients  precludes  the  use  of 
high  dose  chemotherapy  with  stem  cell  rescue in 
a    substantial  fraction  of  patients,  thus  limiting  the 
therapeutic options and the possible benefit derived 
from  myeloablative  regimens.  Management  of 
  Richter’s  syndrome  therefore  remains  unsatisfac-
tory with overall response rates of around 34% using 
CHOP or platinum containing chemotherapy, and 47% 
using rituximab-containing regimen. The mean overall 
survival is around 8 months from end of treatment.96 
Responses to ABVD in cases of Hodgkin’s transfor-
mation are barely any better.97 This has led investiga-
tors to test several other experimental regimens.
In particular, the hyper-CVXD regimen (dexam-
ethasone, cyclophosphamide, vincristine, doxorubi-
cin, cytarabine) induced a response in 41% of patients 
with RS (CR rate of 38%), with a median overall sur-
vival duration of 10 months.98 When compared with 
hyper-CVXD alone, hyper-CVXD plus rituximab and 
GM-CSF alternating with methotrexate and cytara-
bine plus rituximab and GM-CSF did not appear to 
improve the rates of response, disease recurrence-free 
survival, or overall survival. Both regimens had com-
parable toxicity, which included neutropenia, throm-
bocytopenia, and infectious complications.
The combination of fludarabine, cytarabine, cyclo-
phosphamide, cisplatin, and GM-CSF (FACPGM) has 
been reported to have limited activity and significant 
toxicity in RS.99 In a Phase II study, FACPGM was 
administered to 22 patients with RS or refractory PLL 
or NHL. FACPGM induced a CR in 1 of 16 patients 
(6%) with RS.
A  single  centre  Phase  I-II  study  run  at  the 
MD    Anderson  using  OFAR  (Oxaliplatin,  Flu-
darabine,  Ara-C  and  Rituximab),  not  specifically 
aimed  at  patients  with  Richter’s  Syndrome,  also 
included  patients  with  chemotherapy  refractory 
CLL.100 OFAR was given in 4 weekly cycles. The 
main aim of the study was to evaluate the role of State-of-the-art in CLL
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platinum-  containing  regimen  in  refractory  CLL. 
There was no maintenance   treatment. The 20 patients 
with    Richter’s  syndrome  had  an  overall  response 
rate of 50% and a response duration of 10 months, 
ie, similar to the historic controls of CHOP-R but 
with added toxicity.
Allogeneic  stem  cell  transplantation  might  be 
a  promising  therapeutic  strategy  for  patients  with 
RS who are fit enough to tolerate transplant related 
  toxicities.101 Eight patients were treated with high-
dose chemotherapy followed by an allogeneic stem 
cell transplant. Five patients were in resistant relapse 
and three others were in sensitive or untreated relapse 
of RS. The median number of previous therapies was 
4  (range,  2–5  therapies).  Six  patients  received  the 
transplant  from  an  HLA-identical  sibling  and  two 
patients  received  the  transplant  from  an  unrelated 
donor. Three patients (38%) achieved durable disease 
remissions and were free of disease at 14 months, 
47 months, and 67 months, including 2 patients who 
received  non-myeloablative  preparative  regimens. 
Five  patients  died  of  treatment-related  toxicities   
(3  patients  within  30  days  of  transplantation). 
According to a non-randomized comparison of two 
RS  cohorts,  the  estimated  cumulative  survival  at   
3 years has been reported to be 75% for patients who 
received allogeneic SCT after a CR, CRu or PR, com-
pared to 27% for patients who responded to initial 
therapy but received no allogeneic SCT.96 Remark-
ably, allogeneic SCT has no benefit in RS patients 
who are refractory to induction regimens.
In  view  of  the  poor  prognosis  of  Richter’s 
  Syndrome, patients should be entered into clinical tri-
als whenever possible. The UKCLL NCRN group is 
currently recruiting into a Phase II study (CHOP-OR) 
using ofatumumab in induction in combination with 
CHOP  followed  by  ofatumumab  maintenance  for 
one year.
perspective
CLL treatment has changed dramatically in the past 
decade and thanks to chemo-immunotherapy remis-
sion durations of several years with improvement in 
overall survival have been achieved. However, not 
all patients benefit from current treatment strategies. 
Future efforts have to focus on evaluating the pleth-
ora of new anti-cancer agents now available for tol-
erability in older patients with co-morbidities. Their 
efficacy has to be assessed after genetically informed 
risk stratification and response prediction that directs 
targeted therapies to the right patient. In view of their 
favourable safety profile, the combination of antibod-
ies with BCR inhibitors might represent an attractive 
and tangible option for these patients. In the longer 
term, the recent WGS and WES data have revealed 
novel pathways of relevance in CLL such as Notch1 
and  the  spliceosome.  Inhibitors  of  these  pathways 
are already undergoing pre-clinical and early clini-
cal evaluation. Besides, we need to establish comple-
mentary ways of assessing response by focussing on 
quality of life and activities of daily living (ADL) 
assessments in addition to survival curves. We hope 
that in future, these personalized approaches will fur-
ther improve outcomes and maybe even cure patients 
with CLL.
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